These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 17098366)

  • 1. Role of biological membranes in the management of Stevens Johnson syndrome--Indian experience.
    Ramakrishnan KM; Sankar J; Venkatraman J
    Burns; 2007 Feb; 33(1):109-11. PubMed ID: 17098366
    [No Abstract]   [Full Text] [Related]  

  • 2. Medications as risk factors of Stevens-Johnson syndrome and toxic epidermal necrolysis in children: a pooled analysis.
    Levi N; Bastuji-Garin S; Mockenhaupt M; Roujeau JC; Flahault A; Kelly JP; Martin E; Kaufman DW; Maison P
    Pediatrics; 2009 Feb; 123(2):e297-304. PubMed ID: 19153164
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk estimates for drugs suspected of being associated with Stevens-Johnson syndrome and toxic epidermal necrolysis: a case-control study.
    Lin MS; Dai YS; Pwu RF; Chen YH; Chang NC
    Intern Med J; 2005 Mar; 35(3):188-90. PubMed ID: 15737140
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Management of cutaneous risk in pharmacovigilance: metabolic predisposition to Stevens-Johnson syndromes and toxic epidermal necrolysis].
    Wolkenstein P
    Therapie; 1996; 51(5):500-1. PubMed ID: 9138383
    [No Abstract]   [Full Text] [Related]  

  • 5. Early gynaecological assessment following Stevens-Johnson syndrome/toxic epidermal necrolysis.
    Madhuri TK; Kremer C
    J Obstet Gynaecol; 2010; 30(8):871-2. PubMed ID: 21126137
    [No Abstract]   [Full Text] [Related]  

  • 6. T-cell receptor and carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis: understanding a hypersensitivity reaction.
    Ko TM; Chen YT
    Expert Rev Clin Immunol; 2012 Jul; 8(5):467-77. PubMed ID: 22882221
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Stevens-Johnson syndrome and toxic epidermal necrolysis; therapy policy in these life-threatening illnesses. Netherlands Work Group Toxic Epidermal Necrolysis].
    van der Meer JB
    Ned Tijdschr Geneeskd; 1996 Jul; 140(30):1538-43. PubMed ID: 8765761
    [No Abstract]   [Full Text] [Related]  

  • 8. Acute generalised exanthematous pustulosis and toxic epidermal necrolysis induced by carbamazepine.
    Goh TK; Pang SM; Thirumoorthy T; Goh SG
    Singapore Med J; 2008 Jun; 49(6):507-10. PubMed ID: 18581028
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Toxic epidermal necrolysis (syndrome Lyell) versus Stevens-Johnson syndrome].
    Jezierska-Krupa B; Hyla-Klekot L
    Pediatr Pol; 1996 Jul; 71(7):615-20. PubMed ID: 8803466
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Practical guidelines for the management of toxic epidermal necrolysis and Stevens-Johnson syndrome.
    Fromowitz JS; Ramos-Caro FA; Flowers FP;
    Int J Dermatol; 2007 Oct; 46(10):1092-4. PubMed ID: 17910723
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stevens-Johnson syndrome and toxic epidermal necrolysis.
    Prendiville J
    Adv Dermatol; 2002; 18():151-73. PubMed ID: 12528405
    [No Abstract]   [Full Text] [Related]  

  • 12. Severe cutaneous adverse reactions to drugs.
    Chia FL; Leong KP
    Curr Opin Allergy Clin Immunol; 2007 Aug; 7(4):304-9. PubMed ID: 17620821
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of intravenous immunoglobulin for Stevens-Johnson syndrome and toxic epidermal necrolysis in children: Report of two cases secondary to anticonvulsants.
    Romero-Tapia SJ; Cámara-Combaluzier HH; Baeza-Bacab MA; Cerino-Javier R; Bulnes-Mendizabal DP; Virgen-Ortega C
    Allergol Immunopathol (Madr); 2015; 43(2):227-9. PubMed ID: 25183634
    [No Abstract]   [Full Text] [Related]  

  • 14. European Dermatology Forum: skin diseases in Europe. Skin diseases with a high public health impact: toxic epidermal necrolysis and Stevens-Johnson syndrome.
    Fritsch P
    Eur J Dermatol; 2008; 18(2):216-7. PubMed ID: 18424404
    [No Abstract]   [Full Text] [Related]  

  • 15. The timing of intravenous immunoglobulin therapy in Stevens-Johnson syndrome and toxic epidermal necrolysis.
    Yeung CK; Lam LK; Chan HH
    Clin Exp Dermatol; 2005 Sep; 30(5):600-2. PubMed ID: 16045716
    [No Abstract]   [Full Text] [Related]  

  • 16. Human leukocyte antigen genotypes in carbamazepine-induced severe cutaneous adverse drug response in Japanese patients.
    Kashiwagi M; Aihara M; Takahashi Y; Yamazaki E; Yamane Y; Song Y; Muramatsu M; Ikezawa Z
    J Dermatol; 2008 Oct; 35(10):683-5. PubMed ID: 19017052
    [No Abstract]   [Full Text] [Related]  

  • 17. Toxic epidermal necrolysis in a child after carbamazepine dosage increment.
    Sevketoglu E; Hatipoglu S; Akman M; Bicer S
    Pediatr Emerg Care; 2009 Feb; 25(2):93-5. PubMed ID: 19225374
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug-induced Lyell and Stevens-Johnson syndromes.
    Prescrire Int; 2009 Feb; 18(99):20-2. PubMed ID: 19391288
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pentoxyfylline in toxic epidermal necrolysis and Stevens-Johnson syndrome.
    Sanclemente G; De la Roche CA; Escobar CE; Falabella R
    Int J Dermatol; 1999 Nov; 38(11):878-9. PubMed ID: 10583942
    [No Abstract]   [Full Text] [Related]  

  • 20. Toxic epidermal necrolysis (TEN) and Stevens-Johnson syndrome (SJS): experience with high-dose intravenous immunoglobulins and topical conservative approach. A retrospective analysis.
    Stella M; Clemente A; Bollero D; Risso D; Dalmasso P
    Burns; 2007 Jun; 33(4):452-9. PubMed ID: 17475410
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.